Virtual Library
Start Your Search
A. Mogi
Author of
-
+
P2.01 - Poster Session with Presenters Present (ID 461)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.01-030 - Prognostic Impact of Stathmin1 Expression in Patients with Non-Small Lung Cancer (ID 4843)
14:30 - 14:30 | Author(s): A. Mogi
- Abstract
Background:
Stathmin 1 is a cytosolic phosphoprotein that plays a crucial role in the control of cellular division and proliferation by regulating microtubule dynamics. In addition, Stathmin1 is associated with tumor growth and progression. Our study aimed to determine differences in overall (OS) and disease free survival (DFS) in patients with non-small lung cancer (NSCLC) stratified by STMN1 tumor expression.
Methods:
Using inmmunohistochemistry, Stathmin1 expression was determined in resection specimens from 423 NSCLC patients. The relationship between Stathmin1 protein expression and overall and disease free survivalwas assessed using Kaplan Meier survival curves and compared using log-rank statistics. Cox proportional hazards regression determined the hazard for death stratified by Stathmin1, adjusting for clnicopathological characteristics.
Results:
The STMN1 protein was expressed in 58% of NSCLC cases, 54% of Adenocarcinoma, 63% of Squamous cell carcinoma, and 100% of large cell neuroendocrine carcinoma (LCNEC) and its expression was significantly associated with advanced T and N factors, advanced pathological stages, positive lymphatic permeation, positive vascular invasion, and poor or mediate differentiation. STMN1 was a negative prognostic factor for OS (hazard ratio [HR], 2.212; 95% confidence interval [CI]: 1.544-3.169; p< 0.001) and DFS (HR, 2.685; 95% CI: 1.897-3.798; p< 0.001). Multivariable analysis confirmed that STMN1 protein expression was an independent predictor of an unfavorable OS (HR, 1.480; 95% CI, 1.006 to 2.176; p = 0.046) and DFS (HR, 1.605; 95% CI, 1.105 to 2.329; p = 0.013) in all NSCLC patients, and of an unfavorable DFS (HR: 2.128, 95% CI, 1.293 to 3.503; p = 0.003) in Stage I NSCLC patients.
Conclusion:
STMN1 expression was an independent prognostic factor for NSCLC, even when restricted to early stage patients.
-
+
P2.04 - Poster Session with Presenters Present (ID 466)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.04-002 - The Efficacy of Postoperative Radiotherapy against Thymic Epithelial Tumors According to Masaoka Staging and WHO Classification (ID 5904)
14:30 - 14:30 | Author(s): A. Mogi
- Abstract
Background:
Postoperative radiotherapy (PORT) against thymic epithelial tumors is mainly performed based on Masaoka staging. However there is no definite indication for PORT, and its efficacy is still controversial. Meanwhile, the relationship between the efficacy of PORT and WHO classification is also unclear. This study aimed to clarify the efficacy of PORT in association with both Masaoka staging and WHO classification.
Methods:
A 262 patients with thymic epithelial tumors surgically treated in our institute from April 1990 to December 2015 were reviewed. The clinicopathological data were retrospectively evaluated for prognosis and recurrence.
Results:
There were 86 patients with stageⅠ, 121 with stageⅡ, 35 with stage Ⅲ, 13 with stage Ⅳa, and 7 with stage Ⅳb thymic epithelial tumors according to Masaoka staging. As for histological type, 37 patients had type A, 50 had type AB, 59 had type B1, 43 had type B2, 44 had type B3, and 29 had type C (thymic carcinoma) according to WHO classification (2004). Eighty cases (30.5%) underwent PORT. Although PORT showed no association with OS (hazard ratio [HR], 0.565; 95% confidence interval [CI], 0.298 to 1.070; p=0.080), there was no recurrence in patients who received PORT. Subgroup analysis of Masaoka staging (stageⅠ-Ⅱ: HR, 2.445; 95% CI, 0.905-6.607; p=0.078, stage Ⅲ-Ⅳ: HR, 0.434; 95% CI, 0.145 to 1.302, p=0.137,) or WHO classification (type A-B1: HR, 2.859; 95% CI, 1.050-7.719, p=0.030, type B2-C: HR, 1.460; 95% CI, 0.502 to 4.248; p=0.488) alone showed no association with prognosis either. However in thymoma patients who were classified in both stageⅢ-Ⅳ and type B2-C group, PORT was associated with better OS (HR, 0.189; 95% CI, 0.049 to 0.724; p=0.015).
Conclusion:
PORT is effective in patients with thyimic epithelial tumors who are classified in both stageⅢ-Ⅳ and type B2-C.
